Oncoimmunology 2020 Apr 16; 9(1):1744897
Patients with locally advanced and metastatic urothelial carcinoma have a low survival rate (median 15.7 months, 13.1-17.8), with only a 23% response rate to monotherapy treatment with anti-PDL1 checkpoint immunotherapy. To identify new therapeutic targets, we profiled the immune regulatory signatures during murine cancer development using the BBN carcinogen and identified an increase in the expression of the T cell inhibitory protein B7-H4 (VTCN1, B7S1, B7X). B7-H4 expression temporally correlated with decreased lymphocyte infiltration. While the increase in B7-H4 expression within the bladder by CD11b
Podojil, Joseph R; Glaser, Alexander P; Baker, Dylan; Courtois, Elise T; Fantini, Damiano; Yu, Yanni; Eaton, Valerie; Sivajothi, Santhosh; Chiang, Mingyi; Das, Arighno; McLaughlin, Kimberly A; Robson, Paul; Miller, Stephen D; and Meeks, Joshua J, "Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma." (2020). Faculty Research 2020. 282.